DE60040740D1 - VERWENDUNG OF INTERLEUkIN-1 MUTEIN ALS IMPFSTOFFADJUVANS - Google Patents

VERWENDUNG OF INTERLEUkIN-1 MUTEIN ALS IMPFSTOFFADJUVANS

Info

Publication number
DE60040740D1
DE60040740D1 DE60040740T DE60040740T DE60040740D1 DE 60040740 D1 DE60040740 D1 DE 60040740D1 DE 60040740 T DE60040740 T DE 60040740T DE 60040740 T DE60040740 T DE 60040740T DE 60040740 D1 DE60040740 D1 DE 60040740D1
Authority
DE
Germany
Prior art keywords
mutein
vaccine
adjuvan
interleukin
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60040740T
Other languages
German (de)
English (en)
Inventor
Richard S Dondero
Herman F Staats
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Duke University
Original Assignee
Celltech Chiroscience Ltd
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Chiroscience Ltd, Duke University filed Critical Celltech Chiroscience Ltd
Application granted granted Critical
Publication of DE60040740D1 publication Critical patent/DE60040740D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE60040740T 1999-12-03 2000-12-04 VERWENDUNG OF INTERLEUkIN-1 MUTEIN ALS IMPFSTOFFADJUVANS Expired - Fee Related DE60040740D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16892899P 1999-12-03 1999-12-03
PCT/US2000/032813 WO2001039803A2 (en) 1999-12-03 2000-12-04 Interleukin-1 muteins useful as vaccine adjuvants

Publications (1)

Publication Number Publication Date
DE60040740D1 true DE60040740D1 (de) 2008-12-18

Family

ID=22613541

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60040740T Expired - Fee Related DE60040740D1 (de) 1999-12-03 2000-12-04 VERWENDUNG OF INTERLEUkIN-1 MUTEIN ALS IMPFSTOFFADJUVANS

Country Status (7)

Country Link
US (2) US6656462B2 (enExample)
EP (1) EP1196193B1 (enExample)
JP (1) JP2003515569A (enExample)
AT (1) ATE413191T1 (enExample)
AU (1) AU1813701A (enExample)
DE (1) DE60040740D1 (enExample)
WO (1) WO2001039803A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270758B1 (en) * 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
EP1931383A1 (en) 2005-09-28 2008-06-18 Cytos Biotechnology AG Interleukin-1 conjugates and uses thereof
WO2008037504A1 (en) * 2006-09-28 2008-04-03 Cytos Biotechnology Ag Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
EP2368570A3 (en) 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US9138470B2 (en) * 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
WO2011100508A2 (en) 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
BR112013000097B1 (pt) 2010-07-02 2022-02-01 The University Of Chicago Polipeptídeo imunogênico isolado, composição imunogênica e seu uso
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2013162746A1 (en) 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
WO2014085767A1 (en) * 2012-11-29 2014-06-05 University Of Rochester Compositions and methods for treating immune conditions, including type1 diabetes
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途
TWI601742B (zh) * 2016-03-23 2017-10-11 國立清華大學 使宿主提早產生抗體及延長抗體保護時間的重組雞介白素１β蛋白質及其應用
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
US20230293652A1 (en) * 2020-07-07 2023-09-21 Orionis Biosciences, Inc. Immunostimulatory adjuvants
US20250177514A1 (en) 2022-01-28 2025-06-05 Pfizer Inc. Coronavirus antigen variants
WO2025027492A1 (en) 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
US5503841A (en) 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
JP2591615B2 (ja) * 1986-03-14 1997-03-19 大塚製薬株式会社 インターロイキン−１β誘導体及び医薬
IT1217314B (it) 1987-02-20 1990-03-22 Sclavo Spa Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
DE69032251T2 (de) * 1989-02-27 1998-08-13 Massachusetts Institute Of Technology, Cambridge, Mass. Il-1, dessen biologische aktivität inhibiert ist
JP3485184B2 (ja) 1989-07-14 2004-01-13 アメリカン サイアナミド カンパニー インターロイキン含有安定ワクチン組成物
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines

Also Published As

Publication number Publication date
AU1813701A (en) 2001-06-12
WO2001039803A3 (en) 2002-02-21
US20040253208A1 (en) 2004-12-16
US20010036452A1 (en) 2001-11-01
JP2003515569A (ja) 2003-05-07
US6656462B2 (en) 2003-12-02
ATE413191T1 (de) 2008-11-15
EP1196193A2 (en) 2002-04-17
WO2001039803A2 (en) 2001-06-07
EP1196193B1 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
DE60040740D1 (de) VERWENDUNG OF INTERLEUkIN-1 MUTEIN ALS IMPFSTOFFADJUVANS
DE69101753D1 (de) Lockvirus Impfstoff.
LU91324I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)-gardasil/silgard
Schijns et al. Immunoadjuvant activities of E. coli-and plasmid-expressed recombinant chicken IFN-α/β, IFN-γ and IL-1β in 1-day-and 3-week-old chickens
Rotman et al. IL‐12 eliminates the Th‐2 dependent protective immune response of mice to larval Strongyloides stercoralis
FI920132A0 (fi) Stabila vaccinkompositioner innehaollande interleukiner.
ATE229978T1 (de) Helicobacter proteine und impstoffe
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
PT815235E (pt) Vacinas para peste
DE69124800D1 (de) Gentechnologisch veränderte bakteriophagen und sie enthaltende impfstoffe
Lofthouse et al. Cytokines as adjuvants for ruminant vaccines
Follador et al. Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
ATE133074T1 (de) Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
WO1999022763A3 (en) Encapsulated immunomodulators useful as vaccine adjuvants
PT858345E (pt) Uso de muteinas de citocinas do tipo selvagem como imunogenios
Ahmed et al. Modulating Effects of Sensory and Autonomic Neuropeptides on Murine Splenocyte Proliferation and Cytokine Secretion Indd by Leishmania Major
Garcia et al. Protective immunity induced by a Trypanosoma cruzi soluble extract antigen in experimental Chagas' disease. Role of interferon γ
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza
Heath et al. Effects of Added Cytokines on Immune Responses and Memory
Heath Heath¹ and JHL Playfair2
Capron et al. The house dust mite allergen
Garotta The in vivo antiviral activity of interleukin-12 is mediated by gamma interferon

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee